My watch list  

Rentschler has been providing healthcare for over 75 years. In this time, the average lifespan in industrialized western countries has increased from 56 years in 1930 to 75 years in 2005 – as a result of the improved healthcare situation. Rentschler is helping to improve healthcare even further with its two subsidiaries: Rentschler Biotechnologie and Rentschler Pharma.

More about Rentschler
  • News

    Vetter and Rentschler Biopharma Further Strengthen their Strategic Alliance

    Rentschler Biopharma and Vetter announced that their strategic collaboration has taken key steps forward. The companies have further strengthened the established framework for their alliance and set up a governance structure, as well as implemented guidelines for their joint approach across ... more

    Rentschler Biopharma entry into cell and gene therapy

    The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre of excellence in innovation advancing the UK's cell and gene therapy industry, and Rentschler Biopharma SE have announced that Rentschler Biopharma will establish their manufacturing capability in Advanced Therapy Medi ... more

    Rentschler Biotechnologie GmbH transforms into European corporation

    Rentschler Biotechnologie GmbH announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017. The Company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational ... more

  • Companies

    Rentschler Biotechnologie GmbH

    Rentschler is a biopharmaceutical contract manufacturer with over 35 years proven track record. As an independent and family-owned company headquartered in Germany our full-service customized solutions range from supporting drug candidate selection by our TurboCell platform, as well as cell ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE